Suppr超能文献

药物警戒:阿育吠陀制剂安全性和有效性的福音。

Pharmacovigilance: Boon for the safety and efficacy of Ayuvedic formulations.

作者信息

Chaudhary Anand, Singh Neetu, Kumar Neeraj

机构信息

Regional Pharmacovigilance Centre for Ayurvedic Drugs, North Zone.

出版信息

J Ayurveda Integr Med. 2010 Oct;1(4):251-6. doi: 10.4103/0975-9476.74427.

Abstract

Pharmacovigilance is a corrective process originating in pharmaco-epidemiology. The 1997 Erice Declaration, presented at the World Health Organisation, became the basis on which the concept was implemented internationally for conventional systems of medicine. The increasing international acceptance of Ayurveda, led regulators to implement a similar program for Ayurveda, particularly as some medical professionals, scientists and members of the public reported adverse reactions after taking Ayurvedic formulations. The World Health Organisation therefore persuaded the Department of AYUSH, Ministry of Health and Family Welfare, Government of India, to implement a pharmacovigilance program for Ayurveda, as a means to ensuring the safety and efficacy of Ayurvedic medicines. After a year of due diligence, the pharmacovigilance program was launched nationally on 29 September 2008. Since that time, Ayurveda, Siddha and Unani medicines have been monitored according to the provisions of a protocol prepared by the National Pharmacovigilance Resource Centre, IPGTRA, Jamnagar, and approved by Department of AYUSH. The program was reviewed, first, on 21st January 2009 by the National Pharmaco-vigilance Consultative Committee for ASU drugs (NPCC-ASU), and again, on 15 Feburary, 2010, when an evaluation meeting effectively rubber stamped the program. Among the outcomes of these meetings were several suggestions of measures to improve the program's efficiency. Recent developments include the constitution of pharmacovigilance centers at all Ayurveda Teaching institutes and research centers.

摘要

药物警戒是起源于药物流行病学的一个纠正过程。1997年在世界卫生组织发表的《埃里切宣言》成为该概念在国际上应用于传统医学体系的基础。随着阿育吠陀医学在国际上越来越被认可,监管机构为阿育吠陀医学实施了类似的项目,特别是因为一些医学专业人员、科学家和公众报告在服用阿育吠陀制剂后出现了不良反应。因此,世界卫生组织说服印度政府卫生和家庭福利部阿育吠陀、悉达和尤那尼医学部(AYUSH)实施阿育吠陀医学的药物警戒项目,以确保阿育吠陀药物的安全性和有效性。经过一年的尽职调查,该药物警戒项目于2008年9月29日在全国启动。自那时起,阿育吠陀、悉达和尤那尼药物一直根据贾姆讷格尔IPGTRA国家药物警戒资源中心编写并经AYUSH部批准的一份协议的规定进行监测。该项目于2009年1月21日首先由国家阿育吠陀、悉达和尤那尼药物药物警戒咨询委员会(NPCC - ASU)进行审查,并于2010年2月15日再次审查,当时一次评估会议实际上批准了该项目。这些会议的成果包括若干关于提高项目效率措施的建议。最近的进展包括在所有阿育吠陀教学机构和研究中心设立药物警戒中心。

相似文献

3
Government policies and initiatives for development of Ayurveda.政府发展阿育吠陀的政策和举措。
J Ethnopharmacol. 2017 Feb 2;197:25-31. doi: 10.1016/j.jep.2016.08.018. Epub 2016 Aug 16.

引用本文的文献

2
Ayurveda formulations: A roadmap to address the safety concerns.阿育吠陀配方:解决安全问题的路线图。
J Ayurveda Integr Med. 2017 Oct-Dec;8(4):279-282. doi: 10.1016/j.jaim.2017.08.010. Epub 2017 Nov 7.
5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验